The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626001242314p
Ethics application status
Help: Ethics application status
Submitted, not yet approved
Date submitted
Help: Date submitted
21/09/2026
Date registered
Help: Date registered
13/10/2026
Date last updated
Help: Date last updated
13/10/2026
Date data sharing statement initially provided
Help: Data sharing statement date
13/10/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Australian Atypical Parkinsonism Project (A2P) Biobank
Scientific title
Australian Atypical Parkinsonism Project (A2P) Biobank
Additional trial identifiers [1] 318353 0
Nil
Universal Trial Number (UTN)
Trial acronym
A2P
Related trial records

Health condition
Health condition(s) studied:
Lewy Body Dementia 343484 0
Progressive Supranuclear Palsy 343485 0
Corticobasal Syndrome 343486 0
Multiple System Atrophy 343487 0
Parkinson's Plus 343488 0
Atypical Parkinsonism 343489 0
Condition category
Condition code
Neurological 339586 339586 0 0
Neurodegenerative diseases
Neurological 339587 339587 0 0
Parkinson's disease

Intervention/exposure
Study type
Observational
Patient registry
True
Target follow-up duration
4
Target follow-up type
Years
Description of the intervention or exposure
Participants will fall into three main groups, 1) atypical parkinsonism's (50-60% of recruited participants), 2) undiagnosed/first presentation parkinsonism (20-30% of recruited participants), and 3) Parkinson's disease (20% of recruited participants).


Participants will complete a number of minimally required assessments (total duration of less than an hour), including:
-blood collection
-condition specific rating scale (i.e. UPDRS, UMSARS, PSPRS)
-Data on primary clinical diagnosis and (if relevant) sub-diagnosis, symptoms, date of onset
-Socioeconomic and familial histories
-Modified Rankin scale
-Hoehn and Yahr scale

They can then opt to also complete further 'core' (entirely optional, approximately 3 hours total) assessments on the same day including:
-MRI (a basic ~30min protocol)
-Neurological and Motor function assessments
-Cognitive function assessments
-Treatment assessments

Lastly they can opt to consent to further substudies, these include several outpatient procedures which will take place over multiple days and require additional time to complete, including:
-Cerebrospinal fluid biopsy
-Skin Biopsy
-An more advanced MRI protocol (45-50-minute total)
-Health economics questionnaire
-Consent to forward contact details to local brain bank*

*Participants can consent to study team forwarding their contact details to the local brain bank team for discussion on this process and what's involved if they choose to consent - please note that the site's involvement only involves forwarding their details, any subsequent discussions/actions are between the study participant and brain bank team and do not involve the study team.

Follow up visits:
After baseline, patients will be followed up at annual (12 monthly) visits until they decide to withdraw, pass away or the trial ends. An additional 6 monthly follow up visit is requested for patients who are newly diagnosed.
Intervention code [1] 335246 0
Not applicable
Description of the comparator or control
No control group - observational registry/biobank
Control group
Uncontrolled

Outcomes
Primary outcome [1] 346868 0
Collection of Blood samples to establish a biobank for future research into Atypical Parkinson's conditions
Timepoint [1] 346868 0
Baseline visit and all subsequent follow up visits until the end of the study period (4 years), participant death or participant withdrawal/discontinuation.
Secondary outcome [1] 467943 0
Compilation of a database containing information on participants diagnostic, sociodemographic and treatment histories for future research use.
Timepoint [1] 467943 0
Recorded at baseline visit, with any changes recorded at subsequent follow up visits until the end of the study period (4 years), participant death or participant withdrawal/discontinuation.
Secondary outcome [2] 467944 0
Compilation of a database containing information on changes in participant's health condition, quality of life, level of function and any disease progression for future research use.
Timepoint [2] 467944 0
Assessments completed at baseline visit and all subsequent follow up visits until the end of the study period (4 years), participant death or participant withdrawal/discontinuation.
Secondary outcome [3] 467945 0
Compilation of a database containing information on any observations of structural changes in the brain for use in future research
Timepoint [3] 467945 0
Imaging completed at baseline visit and all subsequent follow up visits until the end of the study period (4 years), participant death or participant withdrawal/discontinuation.
Secondary outcome [4] 467946 0
Collection of Cerebrospinal fluid (or CSF) samples to establish a biobank for future research into Atypical Parkinson's conditions
Timepoint [4] 467946 0
Baseline visit and all subsequent follow up visits until the end of the study period (4 years), participant death or participant withdrawal/discontinuation.
Secondary outcome [5] 467947 0
Collection of Skin samples to establish a biobank for future research into Atypical Parkinson's conditions
Timepoint [5] 467947 0
Baseline visit and all subsequent follow up visits until the end of the study period (4 years), participant death or participant withdrawal/discontinuation.

Eligibility
Key inclusion criteria
A broad spectrum of participants will be recruited to the A2P biobank, covering first presentation to severe disease, and all parkinsonian syndromes. Participants will fall into three main groups, 1) atypical parkinsonisms, 2) undiagnosed/first presentation parkinsonism and 3) Parkinson's Disease.
-All disease stages included
-Undiagnosed participants will be recruited at first presentation to capture biomarkers pre-diagnosis for the identification of early diagnostic biomarkers
-Participants with PD will be recruited to enable the evaluation of differential diagnostic measures.

7.1.1. Inclusion Criteria:
• >35 years
• Diagnosis and/or symptoms of atypical parkinsonism and/or Parkinson’s disease
• Willing and able to provide written informed consent



Minimum age
35 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
7.1.2. Exclusion Criteria:
• <35 years of age
• Unable to provide written informed consent
• Secondary parkinsonism (drug/injury-induced or similar)
• Participants with a history of cancer (other than skin or in situ prostate cancer) within the previous five years
• Any significant disease or unstable medical condition that could affect test results
• Other significant neurological illness, including clinically significant (i.e., disabling) stroke, multiple sclerosis, or Alzheimer’s disease. A history of minor stroke or stable epilepsy are not exclusionary;
• Additional exclusion criteria for the lumbar puncture procedure include active infections/skin rash, uncontrolled headaches, immunodeficiency, and uncontrolled epilepsy or blood clotting abnormalities.

Study design
Purpose
Screening
Duration
Longitudinal
Selection
Defined population
Timing
Both
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 30217 0
The Alfred - Melbourne
Recruitment postcode(s) [1] 46661 0
3004 - St Kilda Road Melbourne

Funding & Sponsors
Funding source category [1] 322914 0
Government body
Name [1] 322914 0
National Collaborative Research Infrastructure Strategy (NCRIS)
Country [1] 322914 0
Australia
Primary sponsor type
University
Name
Monash University
Address
Country
Australia
Secondary sponsor category [1] 325953 0
None
Name [1] 325953 0
Address [1] 325953 0
Country [1] 325953 0

Ethics approval
Ethics application status
Submitted, not yet approved
Ethics committee name [1] 321340 0
Alfred Hospital Ethics Committee
Ethics committee address [1] 321340 0
Ethics committee country [1] 321340 0
Australia
Date submitted for ethics approval [1] 321340 0
02/09/2026
Approval date [1] 321340 0
Ethics approval number [1] 321340 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 153418 0
A/Prof Lucy Vivash
Address 153418 0
Monash University - Department of Neuroscience | Level 6 Alfred Centre, 99 Commercial Rd, Melbourne, Vic, 3004
Country 153418 0
Australia
Phone 153418 0
+61 3 9903 0860
Fax 153418 0
Email 153418 0
Contact person for public queries
Name 153419 0
A/Prof Lucy Vivash
Address 153419 0
Monash University - Department of Neuroscience | Level 6 Alfred Centre, 99 Commercial Rd, Melbourne, Vic, 3004
Country 153419 0
Australia
Phone 153419 0
+61 3 99030121
Fax 153419 0
Email 153419 0
Contact person for scientific queries
Name 153420 0
A/Prof Lucy Vivash
Address 153420 0
Monash University - Department of Neuroscience | Level 6 Alfred Centre, 99 Commercial Rd, Melbourne, Vic, 3004
Country 153420 0
Australia
Phone 153420 0
+61 3 99030121
Fax 153420 0
Email 153420 0

Data sharing statement
Will the study consider sharing individual participant data?
No
No IPD sharing reason/comment: Individual participant results will not be shared. If any of these results are of clinical significance with implications for the health of the participant they will be shared with the site study doctor who will then action appropriately and contact the participants regular physicians

Group data will be made available to patients in the form of a study newsletter shared,




What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.